AIMS: To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. METHODS AND RESULTS: Routine electrocardiograms taken throughout the study were assessed by Minnesota-code criteria for the presence of new Q-waves without clinical presentation and analysed with blinding to treatment allocation and clinical outcome. Of all MIs, 36.8% were silent. Being male, older age, longer diabetes duration, prior cardiovascular disease (CVD), neuropathy, higher HbA(1c), albuminuria, high serum creatinine, and insulin use all significantly predicted risk of clinical or silent MI. Fenofibrate reduced MI (clinical or silent) by 19% [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69-0.94; P = 0.006], non-fatal clinical MI by 24% (P = 0.01), and silent MI by 16% (P = 0.16). Among those having silent MI, fenofibrate reduced subsequent clinical CVD events by 78% (HR 0.22, 95% CI 0.08-0.65; P = 0.003). CONCLUSION: Silent and clinical MI have similar risk factors and increase the risk of future CVD events. Fenofibrate reduces the risk of a first MI and substantially reduces the risk of further clinical CVD events after silent MI, supporting its use in type 2 diabetes.
RCT Entities:
AIMS: To determine the incidence and predictors of, and effects of fenofibrate on silent myocardial infarction (MI) in a large contemporary cohort of patients with type 2 diabetes in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. METHODS AND RESULTS: Routine electrocardiograms taken throughout the study were assessed by Minnesota-code criteria for the presence of new Q-waves without clinical presentation and analysed with blinding to treatment allocation and clinical outcome. Of all MIs, 36.8% were silent. Being male, older age, longer diabetes duration, prior cardiovascular disease (CVD), neuropathy, higher HbA(1c), albuminuria, high serum creatinine, and insulin use all significantly predicted risk of clinical or silent MI. Fenofibrate reduced MI (clinical or silent) by 19% [hazard ratio (HR) 0.81, 95% confidence interval (CI) 0.69-0.94; P = 0.006], non-fatal clinical MI by 24% (P = 0.01), and silent MI by 16% (P = 0.16). Among those having silent MI, fenofibrate reduced subsequent clinical CVD events by 78% (HR 0.22, 95% CI 0.08-0.65; P = 0.003). CONCLUSION: Silent and clinical MI have similar risk factors and increase the risk of future CVD events. Fenofibrate reduces the risk of a first MI and substantially reduces the risk of further clinical CVD events after silent MI, supporting its use in type 2 diabetes.
Authors: Monica C Stiles; Elizabeth R Seaquist; Jean Francois Yale; Jennifer B Green; Lois Anne Katz; Sarah Kempainen; Laney S Light; Patricia V Pepper; Zhu-Ming Zhang; Elsayed Z Soliman Journal: J Diabetes Complications Date: 2012-03-24 Impact factor: 2.852
Authors: Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White Journal: Nat Rev Cardiol Date: 2012-08-25 Impact factor: 32.419
Authors: Gilles R Dagenais; Jiang Lu; David P Faxon; Peter Bogaty; Dale Adler; Francisco Fuentes; Jorge Escobedo; Ashok Krishnaswami; James Slater; Robert L Frye Journal: J Am Coll Cardiol Date: 2013-02-19 Impact factor: 24.094
Authors: Kwok-Leung Ong; Andrzej S Januszewski; Rachel O'Connell; Alicia J Jenkins; Aimin Xu; David R Sullivan; Philip J Barter; Wei-Ting Hung; Russell S Scott; Marja-Riitta Taskinen; Anthony C Keech; Kerry-Anne Rye Journal: Diabetologia Date: 2014-11-26 Impact factor: 10.122
Authors: Zhu-Ming Zhang; Pentti M Rautaharju; Ronald J Prineas; Carlos J Rodriguez; Laura Loehr; Wayne D Rosamond; Dalane Kitzman; David Couper; Elsayed Z Soliman Journal: Circulation Date: 2016-05-16 Impact factor: 29.690